EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase III)Randomisierte kontrollierte StudieÄquivalenzstudie

Efficacy and safety of adamgammadex for reversing rocuronium-induced deep neuromuscular block: a multicentre, randomised, double-blind, positive-controlled phase III trial

Yanhua Zhao, Yuqing Ren, Wenqin Xie, Yulan Wang, Yishan Lei, Yingxia Zhu, Xiaoqing Zhang, Xiaozhi Wu, Xiaoming Guo, Yingying Jiang, Saiying Wang, Qian Lei und 16 weitere

British Journal of Anaesthesia · 2025

DOI: 10.1016/j.bja.2025.04.031 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift British Journal of Anaesthesia, 2025. Verfasst von Yanhua Zhao und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anaesthesiology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Key Laboratory of Anaesthesiology …. Hauptthemen laut MEDLINE: Rocuronium, Neuromuscular Blockade, Neuromuscular Nondepolarizing Agents, gamma-Cyclodextrins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Adamgammadex, a newly developed modified γ-cyclodextrin derivative, has demonstrated efficacy in reversing deep rocuronium-induced neuromuscular block in early clinical trials. METHODS: This multicentre, randomised, double-blind, positive-controlled, noninferiority phase III clinical trial aimed to investigate the efficacy and safety of adamagammadex compared with sugammadex in reversing deep rocuronium-induced neuromuscular block. In total, 321 patients were randomly assigned to either the adamgammadex 8 mg kg-1 group or the sugammadex 4 mg kg-1 group. The primary outcome was the success rate of antagonism, defined as recovery of the train-of-four ratio (TOFR) to 0.9 within 10 min. Standard safety data were collected throughout the trial period. RESULTS: For the primary efficacy outcome, the success rate for recovery of TOFR to 0.9 was 98.7% in the adamgammadex group and 100% in the sugammadex group, with an observed difference of -1.3% (95% confidence interval [CI] -4.6%, 1.2%). The lower limit of -4.6% was higher than the noninferiority margin of -10%. For the key secondary efficacy outcomes, the median (interquartile range) time from administration of adamgammadex or sugammadex to recovery of TOFR to 0.9 was 2.5 (2.0, 3.2) min and 2.2 (1.7, 2.7) min, respectively. The difference was 0.5 min (95% CI 0.3, 0.7), and the upper limit of 0.7 min was lower than the noninferiority margin of 5 min. We observed no inferiority in secondary efficacy outcomes. There was no significant difference in the safety profile between adamgammadex and sugammadex. CONCLUSIONS: Adamgammadex was noninferior to sugammadex in reversing deep neuromuscular block from rocuronium. CLINICAL TRIAL REGISTRATION: Chinese Clinical Trial Registry (ChiCTR2200056471, registered February 6, 2022; https://www.chictr.org.cn/showproj.html?proj=141077).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RocuroniumNeuromuscular BlockadeNeuromuscular Nondepolarizing Agentsgamma-CyclodextrinsSugammadexHumansDouble-Blind MethodMaleFemaleMiddle AgedAdultAgedAnesthesia Recovery PeriodTreatment OutcomeYoung Adult

Stichwörter der Autor:innen

adamgammadexneuromuscular blocking agentsphase III studyreversal agentssugammadex

Substanzen

RocuroniumNeuromuscular Nondepolarizing Agentsgamma-CyclodextrinsSugammadex

Autor:innen und Institutionen

  • Department of Anaesthesiology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Key Laboratory of Anaesthesiology (Shanghai Jiao Tong University), Ministry of Education, Shanghai, Chin…
  • Department of Anaesthesiology, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, China.
  • Department of Anaesthesiology, The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Department of Anaesthesiology, Tongji Hospital of Tongji University, Shanghai, China.
  • Department of Anaesthesiology, The 900 Hospital of the Chinese People's Liberation Army Joint Logistic Support Force, Fuzhou, China.
  • Department of Anaesthesiology, West China Hospital, Sichuan University, Chengdu, China.

Zitieren

APA

Zhao, Y., Ren, Y., Xie, W., Wang, Y., Lei, Y., Zhu, Y., Zhang, X., Wu, X., Guo, X., Jiang, Y., Wang, S., Lei, Q., You, J., Yu, Y., Zhou, Y., Zhou, W., Xu, G., Li, C., Gu, Z., …, & Yu, W. (2025). Efficacy and safety of adamgammadex for reversing rocuronium-induced deep neuromuscular block: a multicentre, randomised, double-blind, positive-controlled phase III trial. British Journal of Anaesthesia. https://doi.org/10.1016/j.bja.2025.04.031

Vancouver

Zhao Y, Ren Y, Xie W, Wang Y, Lei Y, Zhu Y, et al. Efficacy and safety of adamgammadex for reversing rocuronium-induced deep neuromuscular block: a multicentre, randomised, double-blind, positive-controlled phase III trial. British Journal of Anaesthesia. 2025. doi:10.1016/j.bja.2025.04.031

BibTeX
@article{Zhao2025,
  author = {Zhao, Yanhua and Ren, Yuqing and Xie, Wenqin and Wang, Yulan and Lei, Yishan and Zhu, Yingxia and Zhang, Xiaoqing and Wu, Xiaozhi and Guo, Xiaoming and Jiang, Yingying and Wang, Saiying and Lei, Qian and You, Jiyue and Yu, Yonghao and Zhou, Yinhui and Zhou, Wenjuan and Xu, Guohai and Li, Chang and Gu, Zhengfeng and Luo, Foquan and Wang, Hongfa and Chen, Junping and Wang, Ruichun and Qi, Youmao and Jie, Qing and Su, Diansan and Gu, Xiyao and Yu, Weifeng},
  title = {Efficacy and safety of adamgammadex for reversing rocuronium-induced deep neuromuscular block: a multicentre, randomised, double-blind, positive-controlled phase III trial},
  journal = {British Journal of Anaesthesia},
  year = {2025},
  doi = {10.1016/j.bja.2025.04.031}
}
Kostenlos starten →